EcoR1 Capital has once again posted strong results.
The life sciences fund headed by Oleg Nodelman was up 29 percent last year, according to an investor.
This is especially impressive given that 2021 was a rough year for many life sciences hedge funds, especially those that load up on fledgling biopharma stocks seeking approval for their first product.
Last
